Abstract
Oral mucosal lesions that are associated with HIV infection can play an important role in guiding the decision to initiate antiretroviral therapy (ART). The incidence of these lesions relative to the timing of ART initiation has not been well characterized. A randomized controlled clinical trial was conducted at the GHESKIO Center in Port-au-Prince, Haiti between 2004 and 2009. 816 HIV-infected ART-naïve participants with CD4 T cell counts between 200 and 350 cells/mm3 were randomized to either immediate ART initiation (early group; N = 408), or initiation when CD4 T cell count was less than or equal 200 cells/mm3 or with the development of an AIDS-defining condition (delayed group; N = 408). Every 3 months, all participants underwent an oral examination. The incidence of oral lesions was 4.10 in the early group and 17.85 in the delayed group (p-value <0.01). In comparison to the early group, there was a significantly higher incidence of candidiasis, hairy leukoplakia, herpes labialis, and recurrent herpes simplex in the delayed group. The incidence of oral warts in delayed group was 0.97 before therapy and 4.27 post-ART initiation (p-value <0.01). In the delayed group the incidence of oral warts post-ART initiation was significantly higher than that seen in the early group (4.27 versus 1.09; p-value <0.01). The incidence of oral warts increased after ART was initiated, and relative to the early group there was a four-fold increase in oral warts if ART was initiated following an AIDS diagnosis. Based upon our findings, candidiasis, hairy leukoplakia, herpes labialis, and recurrent herpes simplex indicate immune suppression and the need to start ART. In contrast, oral warts are a sign of immune reconstitution following ART initiation.
Highlights
There are 35.0 million people living with HIV infection
The incidence of oral warts increased after antiretroviral therapy (ART) was initiated, and relative to the early group there was a four-fold increase in oral warts if ART was initiated following an AIDS diagnosis
In the delayed group the total follow up time prior to therapy was 618.3 years, and the total follow up time after ART initiation was 210.7 years
Summary
There are 35.0 million people living with HIV infection. The majority of these individuals live in resource limited settings where initiation of antiretroviral therapy (ART) must occur in a cost conscious manner [1]. It is estimated that 2.0% of adults between the ages of 15 and 49 are infected [2] In this context simple tools such as the oral examination can provide important clinical information about HIV disease progression and the need to initiate ART [3,4,5,6]. Since HIV-associated oral lesions have diverse etiologies ranging from microbial to malignant to idiopathic [12], it is important to characterize how the timing of ART initiation, and by extension the immune landscape of the host, alters the incidence of these lesions This information will enhance the utility of the oral examination in an era when our approach to treatment is rapidly changing. In this study we use randomized clinical trial data is to understand how CD4 T cell counts and the timing of ART initiation affect the incidence of HIV-associated oral lesions
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
